GlassScriptPhysician profile
Amy Zangger Eby
NPI 1982825436
$2,470.25
in general payments reported to CMS, 2019-2025
23 companies · $744 in 2025
The $744 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $393 · 2023: $600 · 2024: $487 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $370.95 | 2023-2025 | |
| Tolmar, INC. | $323.68 | 2023-2025 | Fensolvi |
| Ascendis Pharma Endocrinology INC | $249.15 | 2022-2025 | Skytrofa |
| Insulet Corporation | $240.04 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $229.76 | 2023-2025 | Sogroya |
| Pfizer INC. | $167.21 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $113.33 | 2021-2025 | Gvoke Hypopen |
| Abbott Laboratories | $109.31 | 2021-2022 | |
| Medtronic, INC. | $90.44 | 2022-2025 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $84.02 | 2023-2025 | Baqsimi |
| Tolmar Pharmaceuticals, INC. | $75.70 | 2021-2022 | |
| Dexcom, INC. | $70.13 | 2021-2024 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $67.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $56.14 | 2025 | Strensiq |
| Intuity Medical INC | $51.12 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38.16 | 2023-2025 | |
| Zealand Pharma US, INC. | $26.26 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.99 | 2023 | Triptodur |
| Amryt Pharma Holdings LTD | $19.42 | 2023 | Myalept |
| Chiesi USA, INC. | $18.93 | 2024 | Myalept |
| Ipsen Biopharmaceuticals, INC | $17.05 | 2021 | |
| Tandem Diabetes Care, INC. | $15.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eton Pharmaceuticals, INC. | $13.73 | 2025 | Khindivi, Alkindi, Increlex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Eby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.